Abstract
Monoclonal antibodies, first introduced in cancer therapy and to prevent allograft rejection, represent new pharmacological tools for the treatment of autoimmune diseases. With the knowledge of immunological movements in autoimmunity, it is now possible to target each single step of the immune process, from the activation of T lymphocytes in lymph nodes to the formation of the immunological synapse, and to T cell differentiation and cytokine production. However, this approach is still not devoid of adverse effects. In fact, even if monoclonal antibodies exert selective immunomodulation by targeting only cells expressing a specific antigen, a widespread perturbation of the immune system is induced, leading to a predisposition for infections and infestations and to the occurrence of tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 256:495–497
Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, Widder P, Rosenberger F, van der Merwe PA, Allen PM, Shaw AS (1998) A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contact. Cell 94:667–677
Huppas JB, Davis MM (2003) T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 3:973–983
Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678–688
Goverman J (2009) Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9:393–407
McLaughin KA, Wucherpfennig KW (2008) B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 98:121–149
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel J-F (2008) Crohn’s disease: beyond antagonists of tumor necrosis factor. Lancet 372:67–81
Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119:2052–2061
Binder M, Vögtle F-N, Michelfelder S, Müller F, Illerhaus G, Sundararajan S, Mertelsmann R, Trepel M (2007) Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 67:3518–3523
Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6:394–403
Steinman L (2009) A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 9:440–447
Carson KR, Focosi D, Major EO, Petrini E, Richey EA, West DP, Bennet CL (2009) Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816–824
Croft M (2009) The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9:271–285
Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104–111
Conflict of interest
The authors certify that there is no actual or potential conflict of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bruno, V., Battaglia, G. & Nicoletti, F. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci 31 (Suppl 3), 283–288 (2011). https://doi.org/10.1007/s10072-010-0382-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-010-0382-6